Here, we showed, for the first time, that 26 weeks of treatment with AO extract alleviated NAFLD-related conditions, along with obesity, hyperlipidemia and hyperglycemia through two key mechanisms of FXR and adiponectin activation in WD-induced mice adjusted to closely mimic the whole spectrum of human NAFLD pathophysiology as accurately as possible. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.